CorMatrix Names Andrew M. Green President and Chief Operating Officer

ROSWELL, Ga.--(BUSINESS WIRE)--CorMatrix® Cardiovascular, Inc. a leading developer of biomaterial compositions and medical devices for regenerative medicine, announced effective January 1, 2016 it has appointed Andrew M. Green as President and Chief Operating Officer and Patrick R. Ferguson as National Sales Director. Mr. Green will have responsibility for the Company's worldwide product lines and operations, reporting to David Camp, CorMatrix's Chairman and Chief Executive Officer. Mr. Ferguson will have responsibility for US Sales and Marketing, and will report to Mr. Green.

"Drew Green's 23 years of demonstrated leadership experience in the medical technology industry have prepared him well to assume the expanded responsibilities of his new role"
Mr. Green joined the company in July 2013 as Vice President Regulatory, Clinical and Quality Affairs and prior to January 1 served as Executive Vice President of Operations. He is credited with consolidating CorMatrix's operations and expediting its product pipeline, including FDA clearance for 3 new products and initiation of clinical trials for 2 product pipelines, while also positioning the business for future growth.

"Drew Green's 23 years of demonstrated leadership experience in the medical technology industry have prepared him well to assume the expanded responsibilities of his new role," said Mr. Camp. "Since joining CorMatrix, Drew has rapidly gained the organization's respect as he moved decisively to strengthen the company's franchise. He also has been involved in a number of corporate initiatives that have given him exposure to various parts of the business and geographic operating entities. I'm extremely pleased to have an executive of Drew's caliber taking an even greater role in helping to build CorMatrix's future."

Prior to joining CorMatrix, Mr. Green held various executive roles in public and private companies including the VP of Regulatory and Clinical Affairs at Halscion, Inc., President and CEO for Oncologix Tech, Inc., principal in NeoMedica, LLC, and Vice President of Scientific Affairs at Novoste Corporation. He started his career as a Scientific Reviewer for the FDA, where he was responsible for the review of scientific, technical, pre-clinical and clinical data submitted in support of the safety and effectiveness of both interventional and general cardiovascular devices. Mr. Green holds a BS degree in Biological Sciences and an MS degree in Bioengineering, both from Clemson University, where his research focused on characterization and use of materials in a biological environment.

Mr. Ferguson joined CorMatrix as an Area Sales Director in November 2012. Bringing over 18 years of leadership and sales experience, he has been instrumental in delivering strategic vision, culture development, and sales excellence to CorMatrix. Since joining the Company, he served as Eastern Area Director and played an integral part in launching the CorMatrix Vascular and Electrophysiology product lines. In addition, Patrick spent 12 years with Medtronic as a District Manager and Senior Sales Rep in their CRM division. He has also held sales roles with St. Jude Medical in their CRM division. Mr. Ferguson received his Bachelor of Science degree from the University of Florida.

"Patrick has demonstrated success in sales and sales management over the years and especially at CorMatrix. We're pleased to expand his responsibilities to include direct leadership of our US Sales and Marketing efforts," said Mr. Green. "We are truly excited about the future growth of CorMatrix and with Patrick's leadership, we're already seeing the initial results of his work."

About CorMatrix

CorMatrix® Cardiovascular, Inc. is a privately held medical device company dedicated to developing and delivering innovative biomaterial devices that harness the body's own innate ability to repair damaged cardiac and vascular tissues. CorMatrix ECM Technology allows surgeons to restore the native anatomy of cardiac and vascular tissue in need of repair, serving as a superior alternative to synthetic or cross-linked materials. Headquartered in Roswell, Georgia, the Company is currently researching, developing and commercializing a platform technology known as CorMatrix® ECM™ for a variety of cardiovascular and other indications, and has U.S. clearance and European registration (with a CE Mark) for its ECM® technology. Since its launch in 2006, CorMatrix® ECM™ Technology has been used at more than 975 hospitals across the U.S. and has been implanted in over 135,000 cardiovascular procedures. Visit cormatrix.com for additional information.

Contacts

Cormatrix Cardiovascular, Inc.
Patricia Cuomo, 678-566-2628
Director of Marketing
 

Read more on